News Quantified

ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder [Yahoo! Finance]

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio [Yahoo! Finance]

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference [Yahoo! Finan

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

13.7%

BEAT

7.7%

MISS

3.8%

BEAT

-4.5%

BEAT

Needham & Company LLC

Form 4 Arcutis Biotherapeutics, For: Jun 14 Filed by: Leonard Keith R

Form 4 Arcutis Biotherapeutics, For: Jun 14 Filed by: Welgus Howard G.

Form 4 Arcutis Biotherapeutics, For: Jun 14 Filed by: LIN SUE-JEAN

Form 4 Arcutis Biotherapeutics, For: Jun 14 Filed by: Curran Terrie

Form 4 Arcutis Biotherapeutics, For: Jun 14 Filed by: Krishnamohan Neha

Top News Gainers

3/19 Form 10-K Arcutis Biotherapeutics, For: Dec 31 33.3%

1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%

3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%

2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%

2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%

4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%

2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%

2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%

2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%

2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%

Top News Decliners

3/16 Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis -16.2%

1/31 Form S-8 Arcutis Biotherapeutics, -5.4%

2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%

4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%

2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%

2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%

2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%

3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day